Ikaria INOmax DS Drug Delivery System: FDA Impose Class I Recall - Erratic Nitric Oxide (NO) Readings
News Jan 05, 2012
Affected serial numbers include DS20070005-DS20100865. This product was manufactured from March 12, 2007 through February 2, 2011 and distributed from September 4, 2007 through February 2, 2011.
BACKGROUND: INOmax DS Delivery System is a drug delivery system used with ventilators to deliver a preset concentration of INOmax therapy gas (nitric oxide for inhalation) for critically ill patients.
RECOMMENDATION: Ikaria implemented a service process change involving the application of DeoxIT, an anti-corrosion lubricant specifically created to prevent fretting corrosion. DeoxIT was added to the preventive maintenance plan for all INOmax DS Drug Delivery Systems and was performed when the Systems rotated through Ikaria’s Regional Service Centers for any routine service activity. On December 22, 2011, Ikaria sent a communication to health care professionals informing them of the completion of this action and that no further action was necessary.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.
Pharmaceutical Pollution Drives Antimicrobial ResistanceNews
In urban streams, persistent pharmaceutical pollution can cause aquatic microbial communities to become resistant to drugs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Scientists Cloak Anti-Cancer Drugs in Particles to Target and Destroy Tumor CellsNews
Scientists now report results showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018